About More Than Scleroderma
Our aim is pretty simple: we want everyone to know more about scleroderma. That's because increasing understanding is the key to improving detection and management of this rare but important disease. That's why Boehringer Ingelheim is supporting More Than Scleroderma, an initiative to increase shared knowledge by bringing people together.
We want people with scleroderma to live the best possible lives. To be more than their disease, not defined by it. But people with scleroderma, their loved ones, caregivers and healthcare professionals cannot do this alone. Boehringer Ingelheim can't do it alone either. But together we can be stronger. Together we can be More than Scleroderma.
Guided by those affected by, and supporting those with, scleroderma
More Than Scleroderma was created following research commissioned by Boehringer Ingelheim in 2016.
The research explored the communication and information needs of everyone who plays a part in a scleroderma journey. This included people who have the condition, their caregivers, and the specialised doctors and nurses who look after them.
The study was conducted in five countries and captured:
The challenges patients face in diagnosis and ongoing care
The information gaps and misunderstandings about the disease
The confusion surrounding the language and terminology in scleroderma
The ways people affected by scleroderma had found to overcome the symptoms and get on
with their lives
The result was the More Than Scleroderma campaign, funded by Boehringer Ingelheim, and validated by patient organisations as well as doctors and nurses who specialise in scleroderma.
Boehringer Ingelheim is committed to improving the lives of people with lung fibrosis
Boehringer Ingelheim is a family-owned company committed to improving the quality of life of people with serious lung conditions.
We have over 90 years of experience researching and developing treatments for lung disease. Since 1921, we have become a leader in this area, making advances in conditions like asthma, chronic obstructive pulmonary disease (COPD), lung cancer and lung fibrosis.
We’re always looking for ways to meet the needs of people with lung conditions. Our research has led to the development of a treatment for idiopathic pulmonary fibrosis (IPF) and we continue to make progress in this field. Our most recent focus is the investigation and treatment of lung fibrosis.